Crescendo Bioscience, Inc. (NASDAQ:MYGN)

CAPS Rating: 3 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Recs

1
Player Avatar whodefenderwho (< 20) Submitted: 1/14/2011 9:36:39 AM : Underperform Start Price: $21.51 MYGN Score: -26.69

ice and again ice

Featured Broker Partners


Advertisement